Companies /Healthcare

Boston Scientific Corp

NYSE: BSX Medical Devices
$48.30
â–² $1.46 (+3.12%) today
Markets closed · 7:22pm ET

Q1 2026 Earnings

Reported Apr 22, 2026, 6:34am ET · SEC source
$0.80
Beat +1.27%
EPS · est. $0.79
$5.2B
Beat +0.60%
Revenue · est. $5.2B
−15.8%
Trailing market
BSX vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+5%+10%+15%Apr 22Apr 23report 6:34am ETearnings+0.4%+15.7%
0+5%+10%+15%Apr 22Apr 23earnings+0.4%+15.7%
BSX +15.7%S&P 500 +0.4%
0+5%+10%+15%Apr 22Apr 23report 6:34am ETearnings+1.0%+15.7%
0+5%+10%+15%Apr 22Apr 23earnings+1.0%+15.7%
BSX +15.7%NASDAQ +1.0%
−5%0+5%+10%Apr 21Apr 30report 6:34am ETearnings+0.9%−4.2%
−5%0+5%+10%Apr 21Apr 30earnings+0.9%−4.2%
BSX −4.2%S&P 500 +0.9%
−5%0+5%+10%Apr 21Apr 30report 6:34am ETearnings+2.4%−4.2%
−5%0+5%+10%Apr 21Apr 30earnings+2.4%−4.2%
BSX −4.2%NASDAQ +2.4%
+8.99%
Day of report
+1.26%
Next session
−11.90%
One week
−10.93%
30 days

S&P 500 over the same 30 days: +4.84%.

Did BSX Beat Earnings? Q1 2026 Results

Boston Scientific posted a convincing beat to open fiscal 2026, with first-quarter revenue of $5.20 billion growing 11.6% year-over-year and adjusted EPS of $0.80 edging past the $0.79 consensus by 1.61%, extending the company's streak of consensus EPS beats to four consecutive quarters. The primary engine behind the quarter was a surging Cardiovascular segment, which generated $3.50 billion in sales at 13.5% reported growth, fueled by strong adoption of devices like the WATCHMAN FLX and FARAPULSE pulsed field ablation system, the latter showing sustained superiority over thermal ablation at four years in long-term trial data. Organic growth of 9.4% exceeded even Boston Scientific's own guidance range of 8.5 to 10.0%, underscoring the breadth of demand across its portfolio. Looking ahead, management guided full-year 2026 adjusted EPS of $3.34 to $3.41 on reported revenue growth of 7.0 to 8.5%, with the sequential deceleration in Q2 guidance reflecting cautious assumptions around tariff-related and macroeconomic uncertainty, even as analysts broadly maintain positive ratings on the stock despite recent share price pressure.

Key Takeaways
  • Cardiovascular segment growth of 13.5% reported driven by strong global adoption
  • Neuromodulation growth of 17.4% reported, strongest sub-segment growth
  • Organic growth of 9.4% exceeded high end of company guidance range
  • Asia Pacific operational growth of 12.0% and Latin America operational growth of 12.0%
  • Category leadership strategy across all business segments

“Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter. We remain focused on executing our long-term strategy and advancing our differentiated pipeline to drive meaningful impact for patients, physicians and hospital systems.”

Boston Scientific CEO, on the earnings call

Forward Guidance & Outlook

For full year 2026, Boston Scientific estimates net sales growth of approximately 7.0 to 8.5 percent on a reported basis and 6.5 to 8.0 percent on an organic basis, with adjusted EPS of $3.34 to $3.41. For Q2 2026, the company estimates net sales growth of approximately 5.5 to 7.5 percent on a reported basis and 5.0 to 7.0 percent on an organic basis, with adjusted EPS of $0.82 to $0.84.

BSX YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$0$2.0B$4.0B$4.7B$5.2BRevenue$2.9B$3.6BGross Profit$896.0M$1.1BOperating Income$674.0M$1.3BNet Income
$0$2.0B$4.0BRevenueGross ProfitOperating IncomeNet Income

BSX Revenue by Segment

Cardiovascular$3.5B+13.5%
Cardiology
MedSurg$1.7B+7.8%
Endoscopy$736.0M+9.4%
Urology$646.0M+2.1%
Peripheral Interventions
Neuromodulation$318.0M+17.4%

BSX Revenue by Geography

United States$3.3B+10.9%
EMEA$932.0M+10.1%
Asia Pacific$803.0M+14.7%
Latin America$185.0M+19.0%

Figures from SEC filings and company reports. Not investment advice.